Tech Company Financing Transactions

Kala Pharmaceuticals Funding Round

Kala Pharmaceuticals closed a $22.5 million Series B financing round on 4/23/2014. Investors included Ysios Capital, Crown Venture Fund and Lux Capital.

Transaction Overview

Company Name
Kala Pharmaceuticals
Announced On
4/23/2014
Transaction Type
Venture Equity
Amount
$22,500,000
Round
Series B
Investors

Ysios Capital (Lead Investor) (Karen Wagner)

Crown Venture Fund (Richard Robb)

Lux Capital (Robert Paull)

Polaris Partners (Kevin Bitterman)

Third Rock Ventures (Robert Tepper)

Proceeds Purpose
The proceeds from the financing will be used to advance clinical development of the company's loteprednol etabonate MPP (LE-MPP) program.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
490 Arsenal Way 120
Watertown, MA 02472
USA
Phone
(781) 996-5252
Website
www.kalarx.com
Email Address
[email protected]
Overview
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is a biotechnology company founded upon a proprietary drug delivery technology. By utilizing this unique technology, Kala aims to address unmet therapeutic needs of various diseases and conditions in a fundamentally novel way.
Profile
Kala Pharmaceuticals LinkedIn Company Profile
Social Media
Kala Pharmaceuticals Company Twitter Account
Company News
Kala Pharmaceuticals News
Facebook
Kala Pharmaceuticals on Facebook
YouTube
Kala Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Iwicki
  Mark Iwicki LinkedIn Profile  Mark Iwicki Twitter Account  Mark Iwicki News  Mark Iwicki on Facebook
Chief Medical Officer
Kim Brazzell
  Kim Brazzell LinkedIn Profile  Kim Brazzell Twitter Account  Kim Brazzell News  Kim Brazzell on Facebook
Chief Operating Officer
Todd Bazemore
  Todd Bazemore LinkedIn Profile  Todd Bazemore Twitter Account  Todd Bazemore News  Todd Bazemore on Facebook
Chief Scientific Officer
Hongming Chen
  Hongming Chen LinkedIn Profile  Hongming Chen Twitter Account  Hongming Chen News  Hongming Chen on Facebook
VP - Finance
Mary Reumuth
  Mary Reumuth LinkedIn Profile  Mary Reumuth Twitter Account  Mary Reumuth News  Mary Reumuth on Facebook
VP - General Counsel
Eric Trachtenberg
  Eric Trachtenberg LinkedIn Profile  Eric Trachtenberg Twitter Account  Eric Trachtenberg News  Eric Trachtenberg on Facebook
VP - Manufacturing
Vincent Kosewski
  Vincent Kosewski LinkedIn Profile  Vincent Kosewski Twitter Account  Vincent Kosewski News  Vincent Kosewski on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/23/2014: Avalanche Biotech venture capital transaction
Next: 4/23/2014: Ondot Systems venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.